INTEGRAL
INTEGRATING A MULTIMODAL APPROACH TO ADDRESS CURRENT CHALLENGES IN IMMUNOTHERAPY
WHY CALL UPON US
• Preclinical mouse models for cancer, brain diseases and infectious diseases • IP-backed sdAb and cell-based therapies from bench to bedside • Molecular Biology Core Facility, featuring viral vector and mRNA platforms • In vivo Cellular and Molecular Imaging Core Facility • GMP Vector Development Unit
General contact: integral@vub.be Valorisation managers: geert.raes@vub.be hilde.revets@vub.be Promotor: jo.van.ginderachter@vub.be Co-promotors: BCIM dlaoui@vub.be kiavash.movahedi@vub.be eva.hadadi@vub.be benoit.stijlemans@vub.be geert.raes@vub.be MITH nick.devoogdt@vub.be tony.lahoutte@vub.be timo.de.groof@vub.be jens.michael.Debacker@vub.be matthias.dHuyvetter@vub.be cleo.goyvaerts@vub.be TORC Karine Breckpot karine.breckpot@vub.be Lorenzo Franceschini lorenzo.franceschini@vub.be
GROUP OF EXCELLENCE IN APPLIED RESEARCH - GEAR
Utilizing the immune system or components thereof has grown to be a powerful therapeutic option in cancer and other diseases. However, not all patients respond equally well to immune-based therapies, highlighting the need for improving immunotherapy outcome. The INTEGRAL IOF program aims to address this issue, by offering services and tools for immune stimulation (ACTIVATION), negating immunosuppressive cues (MODULATION), steering drug development (analysis of MODE OF ACTION and THERAPY RESISTANCE MECHANISMS) and driving patient selection and monitoring of therapy response (via in vivo IMAGING).
CONTACT